{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:36Z","timestamp":1791421116617,"version":"4.3.3"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spectrum Pharmaceuticals, Inc"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.critrevonc.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T06:53:28Z","timestamp":1468738408000},"page":"5-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Zevalin\u00ae (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?"],"prefix":"10.1016","volume":"105","author":[{"given":"David","family":"Rizzieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.07.008_bib0005","series-title":"American Cancer Society: Cancer Facts & Figs","author":"American Cancer Society","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00277-014-2145-6","article-title":"Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life","volume":"93","author":"Andrade-Campos","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2015.02.025","article-title":"Patients older than 65 years with non-Hodgkin lymphoma are suitable for treatment with (90)Yttrium-ibritumumab tiuxetan: a single institution experience","volume":"15","author":"Andrade-Campos","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0020","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-014-2288-5","article-title":"Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab","volume":"94","author":"Berinstein","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0030","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3324\/haematol.2013.093450","article-title":"Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial","volume":"99","author":"Briones","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0040","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2013-0079","article-title":"Bendamustine in indolent non-Hodgkin\u2019s lymphoma: a practice guide for patient management","volume":"18","author":"Brugger","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0045","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0050","first-page":"391","article-title":"Radioimmunotherapy of non-Hodgkin\u2019s lymphoma: from the magic bullets to radioactive magic bullets","volume":"84","author":"Chamarthy","year":"2011","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.660","article-title":"The new World Health Organization classification of lymphomas: the past, the present and the future","volume":"19","author":"Chan","year":"2001","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0065","first-page":"1017","article-title":"Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma","volume":"15","author":"Chinn","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0070","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1309\/3WG32YRAMQ7RB9D4","article-title":"Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study","volume":"126","author":"Chu","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0075","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0080","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0085","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.seminoncol.2005.01.011","article-title":"Concepts in radioimmunotherapy and immunotherapy: radioimmunotherapy from a Lym-1 perspective","volume":"32","author":"DeNardo","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0090","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","article-title":"High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation","volume":"26","author":"Devizzi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0095","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.2013.50.2922","article-title":"Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM","volume":"31","author":"Devizzi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/00006231-200309000-00002","article-title":"The radiation biology of radioimmunotherapy","volume":"24","author":"Dixon","year":"2003","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0105","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.07.008_bib0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.47.43","article-title":"Radioimmunotherapy for non-hodgkin lymphoma: historical perspective and current status","volume":"47","author":"Emmanouilides","year":"2007","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0115","series-title":"54th Annual Meeting of the American Society of Hematology","author":"Flinn","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0120","series-title":"Holland-Frei Cancer Medicine","article-title":"Pathology, immunobiology, and natural history of NHL","author":"Freedman","year":"2003"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djk155","article-title":"Users fear that lymphoma drugs will disappear","volume":"99","author":"Garber","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0130","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","article-title":"Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma","volume":"5","author":"Gordon","year":"2004","journal-title":"Clin. Lymphoma"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0140","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0145","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1002\/cncr.26182","article-title":"Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia\/acute myelogenous leukemia","volume":"117","author":"Guidetti","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2015.04.005","article-title":"Autologous hematopoietic stem cell transplantation in elderly patients (\u226570 years) with non-Hodgkin's lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study","volume":"6","author":"Hermet","year":"2015","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0155","series-title":"FDA Removes Ibritumomab Bioscan Requirement","author":"Hitt","year":"2011"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0160","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00259-014-2758-y","article-title":"Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network","volume":"41","author":"Hohloch","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","article-title":"Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria","volume":"32","author":"Illidge","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0175","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","article-title":"Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date","volume":"28","author":"Illidge","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.beha.2006.05.004","article-title":"Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma","volume":"19","author":"Inwards","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0185","first-page":"3","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","volume":"52","author":"Jaffe","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0195","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/annonc\/mdi248","article-title":"High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study","volume":"16","author":"Josting","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0200","first-page":"27","article-title":"The roles of radiotherapy and immunotherapy for the treatment of lymphoma","volume":"5","author":"Kimball","year":"2013","journal-title":"Mol. Cell Pharmacol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2011.07.016","article-title":"Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy-versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma","volume":"18","author":"Krishnan","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0210","series-title":"56th Annual Meeting of the American Society of Hematology","article-title":"Short course of bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan in patients with chemotherapy-naive follicular lymphoma: results of Fol-Brite","author":"Lansigan","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.leu.2402320","article-title":"Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies","volume":"16","author":"Ma","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0220","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3109\/10428194.2014.1001987","article-title":"High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma","volume":"56","author":"Martin","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0225","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/MNM.0000000000000172","article-title":"90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution","volume":"35","author":"Matesan","year":"2014","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0230","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.bbmt.2014.07.028","article-title":"Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen","volume":"20","author":"Mei","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/157488807781696230","article-title":"Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90ibritumomab tiuxetan","volume":"2","author":"Molina","year":"2007","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0240","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III. trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0245","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line lndolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0250","series-title":"National Cancer Institute: NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s Lymphomas","author":"NCCN","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0255","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0260","series-title":"Combination Chemotherapy or 90-yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients with Relapsed Diffuse Large \u00df-cell Non-Hodgkin Lymphoma (SPINOZA)","author":"National Institute of Health","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0265","series-title":"Zevalin Before Stem Cell Transplant in Treating Patients with Non-Hodgkin Lymphoma","author":"National Institute of Health","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0270","series-title":"Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients with Relapsed Aggressive B-Cell NHL","author":"National Institute of Health","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0275","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/01.mnm.0000224467.74545.27","article-title":"Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma","volume":"27","author":"Otte","year":"2006","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0280","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0285","first-page":"1291","article-title":"The pathologist's view point: part I\u2014indolent lymphomas","volume":"85","author":"Pileri","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0290","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/JCO.2008.18.5447","article-title":"Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas","volume":"26","author":"Press","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0295","first-page":"509","article-title":"Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high\u2013tumor-burden follicular lymphoma: a Wisconsin Oncology Network study","volume":"12","author":"Rajguru","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0300","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11523-014-0324-y","article-title":"The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma","volume":"10","author":"Read","year":"2015","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0305","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0310","series-title":"SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma","author":"SEER Cancer Statistics Factsheets","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0320","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2967\/jnumed.109.073155","article-title":"Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U: S. medical oncologists and hematologists","volume":"51","author":"Schaefer","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0325","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.110.085589","article-title":"Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists","volume":"52","author":"Schaefer","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0330","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0335","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","article-title":"Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma","volume":"35","author":"Shimoni","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0340","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1705919","article-title":"Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma","volume":"41","author":"Shimoni","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0345","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0350","first-page":"0","article-title":"Effect of radioimmunotherapy-based poor-risk molecular profiling in diffuse large B-cell lymphoma","volume":"3","author":"Siddiqi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0355","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody","volume":"43","author":"Wagner","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0360","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/bmt.2011.109","article-title":"Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation","volume":"47","author":"Waterman","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0365","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0370","first-page":"1198","article-title":"Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma","volume":"28","author":"Wiseman","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0375","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0380","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.10305","article-title":"Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma","volume":"94","author":"Wiseman","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0385","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0390","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0395","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0400","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0405","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.13493","article-title":"A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I\/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402","volume":"170","author":"Witzig","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0410","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1358\/dof.2002.027.06.681745","article-title":"Zevalin\u2122","volume":"27","author":"Witzig","year":"2002","journal-title":"Drugs Future"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0415","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2011.08991.x","article-title":"Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation","volume":"157","author":"Wondergem","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0420","series-title":"package Insert]","author":"Zevalin","year":"2013"},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0425","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminhematol.2008.02.002","article-title":"Radioimmunotherapy-based conditioning regimens for stem cell transplantation","volume":"45","author":"Zhang","year":"2008","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.critrevonc.2016.07.008_bib0430","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.semnuclmed.2003.11.005","article-title":"Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Zhu","year":"2004","journal-title":"Semin. Nucl. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T21:30:14Z","timestamp":1589664614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":86,"alternative-id":["S1040842816301640"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zevalin\u00ae (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}